NO315546B1 - Inhibisjon av retro virusinfeksjon - Google Patents
Inhibisjon av retro virusinfeksjon Download PDFInfo
- Publication number
- NO315546B1 NO315546B1 NO19950897A NO950897A NO315546B1 NO 315546 B1 NO315546 B1 NO 315546B1 NO 19950897 A NO19950897 A NO 19950897A NO 950897 A NO950897 A NO 950897A NO 315546 B1 NO315546 B1 NO 315546B1
- Authority
- NO
- Norway
- Prior art keywords
- slpi
- hiv
- cells
- infection
- mutein
- Prior art date
Links
- 206010038997 Retroviral infections Diseases 0.000 title abstract description 4
- 230000005764 inhibitory process Effects 0.000 title description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 4
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 29
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 abstract description 32
- 208000031886 HIV Infections Diseases 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 8
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 6
- 210000005260 human cell Anatomy 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 14
- 210000001616 monocyte Anatomy 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 9
- 229960002555 zidovudine Drugs 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 208000030507 AIDS Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 239000003443 antiviral agent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940124522 antiretrovirals Drugs 0.000 description 3
- 239000003903 antiretrovirus agent Substances 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000005074 Retroviridae Infections Diseases 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000006320 pegylation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000933179 Homo sapiens Cathepsin G Proteins 0.000 description 1
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 1
- 101000820585 Homo sapiens SUN domain-containing ossification factor Proteins 0.000 description 1
- 101000673946 Homo sapiens Synaptotagmin-like protein 1 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101150064785 SLPI gene Proteins 0.000 description 1
- 102100021651 SUN domain-containing ossification factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004206 promonocyte Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94336992A | 1992-09-09 | 1992-09-09 | |
| PCT/US1993/008486 WO1994006454A2 (en) | 1992-09-09 | 1993-09-09 | Inhibitiion of retrovirus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO950897L NO950897L (no) | 1995-03-08 |
| NO950897D0 NO950897D0 (no) | 1995-03-08 |
| NO315546B1 true NO315546B1 (no) | 2003-09-22 |
Family
ID=25479533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19950897A NO315546B1 (no) | 1992-09-09 | 1995-03-08 | Inhibisjon av retro virusinfeksjon |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0666755B1 (pt) |
| JP (2) | JP3517238B2 (pt) |
| KR (1) | KR100273620B1 (pt) |
| AT (1) | ATE238062T1 (pt) |
| AU (1) | AU681350B2 (pt) |
| CA (1) | CA2141951C (pt) |
| CZ (1) | CZ286953B6 (pt) |
| DE (1) | DE69332904T2 (pt) |
| DK (1) | DK0666755T3 (pt) |
| ES (1) | ES2197153T3 (pt) |
| FI (1) | FI951078A0 (pt) |
| HU (1) | HU218892B (pt) |
| NO (1) | NO315546B1 (pt) |
| NZ (1) | NZ256246A (pt) |
| OA (1) | OA10133A (pt) |
| PL (1) | PL307864A1 (pt) |
| PT (1) | PT666755E (pt) |
| RO (1) | RO116164B1 (pt) |
| RU (1) | RU2126266C1 (pt) |
| SG (1) | SG48115A1 (pt) |
| SK (1) | SK281127B6 (pt) |
| UA (1) | UA41338C2 (pt) |
| WO (1) | WO1994006454A2 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9507165A (pt) * | 1994-03-23 | 1997-09-09 | Tokyo Tanase Company Limited | Inibidor da triptase clara agente terapêutico ou profilático para doenças virais processo terapêutico para doenças virais e uso da antileucoprotease |
| WO1997003694A1 (fr) * | 1995-07-24 | 1997-02-06 | Tokyo Tanabe Company Limited | Remede contre les affections virales |
| ES2246498T3 (es) | 1995-11-13 | 2006-02-16 | Vitaleech Bioscience N.V. | Aislados antivirales obtenidos de sanguijuelas. |
| US7276333B1 (en) | 1999-05-13 | 2007-10-02 | Japan Science And Technology Agency | Viral infection inhibitor targeting integrase N-terminal domain |
| DE10101792B4 (de) * | 2001-01-17 | 2004-03-18 | Vivotec Biomedical Technologies Gmbh | Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern |
| US8288439B2 (en) | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340877C (en) * | 1987-12-28 | 2000-01-18 | Takashi Sugiyama | Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology |
| JP2804979B2 (ja) * | 1988-11-28 | 1998-09-30 | 日本ケミカルリサーチ株式会社 | エイズ治療および阻害剤 |
| CA2007083A1 (en) * | 1989-01-09 | 1990-07-09 | Nobuhiko Katunuma | Pharmaceutical use of trypstatin |
| DK0491878T3 (da) * | 1989-08-16 | 1997-06-23 | Chiron Corp | Præparater til inhibering af proteinhormondannelse og anvendelser deraf |
| WO1991008769A1 (fr) * | 1989-12-18 | 1991-06-27 | Transgene S.A. | Composition pharmaceutique destinee au traitement ou a la prevention des infections retrovirales |
| GR1001044B (el) * | 1991-06-03 | 1993-04-28 | Logothetou Rella Eleni | Μηχανισμός διή?ησης νεοπλασματικών κυττάρων και η χρήση του αναστολέα της Ca2+ -εξαρτώμενης ουδέτερης πρωτεάσης για την παρασκευή φαρμακευτικών αντικαρκινικών συν?έσεων. |
-
1993
- 1993-09-09 AT AT93921439T patent/ATE238062T1/de not_active IP Right Cessation
- 1993-09-09 RU RU95109909A patent/RU2126266C1/ru not_active IP Right Cessation
- 1993-09-09 PT PT93921439T patent/PT666755E/pt unknown
- 1993-09-09 UA UA95048317A patent/UA41338C2/uk unknown
- 1993-09-09 CZ CZ1995559A patent/CZ286953B6/cs not_active IP Right Cessation
- 1993-09-09 JP JP50816294A patent/JP3517238B2/ja not_active Expired - Fee Related
- 1993-09-09 SK SK297-95A patent/SK281127B6/sk unknown
- 1993-09-09 EP EP93921439A patent/EP0666755B1/en not_active Expired - Lifetime
- 1993-09-09 DE DE69332904T patent/DE69332904T2/de not_active Expired - Fee Related
- 1993-09-09 WO PCT/US1993/008486 patent/WO1994006454A2/en active IP Right Grant
- 1993-09-09 ES ES93921439T patent/ES2197153T3/es not_active Expired - Lifetime
- 1993-09-09 DK DK93921439T patent/DK0666755T3/da active
- 1993-09-09 AU AU48530/93A patent/AU681350B2/en not_active Ceased
- 1993-09-09 RO RO95-00493A patent/RO116164B1/ro unknown
- 1993-09-09 PL PL93307864A patent/PL307864A1/xx unknown
- 1993-09-09 HU HU9500682A patent/HU218892B/hu not_active IP Right Cessation
- 1993-09-09 NZ NZ256246A patent/NZ256246A/xx not_active IP Right Cessation
- 1993-09-09 CA CA002141951A patent/CA2141951C/en not_active Expired - Fee Related
- 1993-09-09 SG SG1996007118A patent/SG48115A1/en unknown
- 1993-09-09 KR KR1019950700929A patent/KR100273620B1/ko not_active IP Right Cessation
-
1995
- 1995-03-08 NO NO19950897A patent/NO315546B1/no unknown
- 1995-03-08 FI FI951078A patent/FI951078A0/fi not_active Application Discontinuation
- 1995-03-09 OA OA60622A patent/OA10133A/en unknown
-
2003
- 2003-07-07 JP JP2003271629A patent/JP2004002455A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU723537B2 (en) | The treatment of HIV and other viral infections using combinatorial therapy | |
| US7335727B2 (en) | Pharmaceutical used for treating HIV infection, the composition and uses thereof | |
| WO1991018010A1 (en) | Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof | |
| US6017880A (en) | Inhibition of retrovirus infection | |
| NO315546B1 (no) | Inhibisjon av retro virusinfeksjon | |
| JPH07267874A (ja) | Ｈｉｖ感染に対する組合せ化学療法 | |
| CN115724919B (zh) | 强效抑制艾滋病病毒及其耐药毒株的新型膜融合抑制剂及其药物用途 | |
| US6869925B1 (en) | Inhibition of retrovirus infection | |
| JPWO2008050830A1 (ja) | 抗ｈｉｖ剤 | |
| WO1990008198A1 (en) | Compositions and methods for treating or preventing aids, arc and hiv infection | |
| US7285621B2 (en) | Multiple branch peptide construction | |
| WO1997025350A1 (en) | Use of chemokines for the treatment and prevention of hiv infection | |
| Pomerantz et al. | Therapy of human immunodeficiency virus infections | |
| Agentsa | Implications for the Design of Small-Peptide | |
| WO2012101614A1 (en) | Antiviral peptides | |
| WO2012101616A1 (en) | Antiviral peptides | |
| WO2012101617A1 (en) | Antiviral peptides | |
| MXPA97009682A (en) | The treatment of hiv infections and other viral infections using a combined therapy | |
| EP0696202A1 (en) | Pharmaceutical composition containing thymoctonan and azt |